DrugPatentWatch Database Preview

Details for Patent: 8,425,934

« Back to Dashboard

Which drugs does patent 8,425,934 protect, and when does it expire?

Patent 8,425,934 protects BRILINTA and is included in one NDA.

This patent has thirty-seven patent family members in thirty-three countries.

Summary for Patent: 8,425,934

Title:	Pharmaceutical compositions
Abstract:	The present invention relates to pharmaceutical compositions and, more particularly, to a pharmaceutical composition containing the compound {1S-[1.alpha.,2.alpha.,3.beta.(1S*,2R*),5.beta.]}-3-(7-{[2-(3,4-difluorop- henyl)cyclopropyl]amino}-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-- 3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol.
Inventor(s):	Banks; Simon (Loughborough, GB)
Assignee:	AstraZeneca AB (Sodertalje, SE)
Application Number:	11/841,030
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,425,934
Patent Claim Types: see list of patent claims	Composition; Compound; Formulation; Dosage form;

Drugs Protected by US Patent 8,425,934

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Astrazeneca Pharms	BRILINTA	ticagrelor	TABLET;ORAL	022433-002	Sep 3, 2015		RX	Yes	No			Y
Astrazeneca Pharms	BRILINTA	ticagrelor	TABLET;ORAL	022433-001	Jul 20, 2011		RX	Yes	Yes			Y

International Family Members for US Patent 8,425,934

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Slovenia	2056832
Singapore	177162
Saudi Arabia	2899
Russian Federation	2012153069